Authors

Rupesh Kotecha, Miami Cancer InstituteFollow

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT# 04511013). 2023 American Society of Clinical Oncology

Publication Date

6-2-2023

Presented At:

ASCO Annual Meeting

Content Type

Poster

Additional Authors:

Additional authors and institutional affiliations

Citation

Kotecha, Rupesh, "A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT# 04511013). 2023 American Society of Clinical Oncology" (2023). All Publications. 4877.
https://scholarlycommons.baptisthealth.net/se-all-publications/4877